Rivastigmine (RVT) is anti-Alzheimer with low bioavailability and with short elimination half-
life due to significant first-pass metabolism. RVT is a hydrophilic drug because it has low …

Objective: In an attempt to optimize the anti-Alzheimer effect, rivastigmine-loaded chitosan
nanoparticles were developed in order to target of brain through skin permeation. Methods …

Here we report a novel approach for preparation of a 6-day transdermal drug delivery
system (TDDS) as treatment for mild to moderate Alzheimer's disease. The spray drying …

Objective: The objective of present investigation was to develop rivastigmine tartrate
transdermal film employing factorial design. Methods: The formulations were designed by …

Memory loss or dementia is a progressive disorder, and one of its common forms is
Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present …

Nanotechnology mediated drug delivery has been reported to enhance the drug efficacy,
bioavailability, reduce toxicity and improve patient compliance by targeting the cells and …

The present study discusses possibility of targeting an anti-Alzheimer's drug rivastigmine
tartarate (RT) to the brain using novel synthesized L-lactide-depsipeptide polymeric …

Purpose Rivastigmine Tartrate (RT) is a reversible cholinesterase inhibitor used for the
treatment of Alzheimer's disease and CNS disorder. The entry of the drug to the brain is …

Biodegradable polymeric nanoparticles loaded Repaglinide were prepared by solvent
extraction method. In this method chitosan, PLA and PCL were employed to prepare …

Terbinafine hydrochloride (TBF-HCl) loaded poly (lactic-co-glycolic acid)(PLGA)
nanoparticles (NPs) were produced by emulsification/solvent evaporation method and were …